First FDA-approved blood test helps early detection of Alzheimer's
BAY COUNTY, Fla. (WMBB) – A simple blood draw has now become a powerful tool in the early fight against Alzheimer's.
The FDA has approved the first blood test to help detect signs of Alzheimer's disease. It's called the Lumipulse test, and it looks for key proteins in the blood that are linked to the disease's early stages.
'There are several blood tests out there. This is the first blood test that has FDA clearance. This test is a biomarker, and we're familiar with biomarkers in other respects. For example, diabetes. You know, there's a blood test to see if there's glucose in the blood or what the blood sugar level is like. So biomarkers help us to detect that something's going on in the body,' Florida Representative for the Alzheimer's Association Stefanie Wardlow said.
Hopeful Hearts provides free virtual support for parents of pediatric cancer patients
Alzheimer's disease is a brain disorder known to slowly destroy memory and thinking skills.Doctors have relied on brain scans or spinal taps for diagnosis, which can be costly and sometimes hard to access. This test could make early diagnosis more available to millions.Early detection gives families more time to plan, start treatment, and even join clinical trials.
'My aunt in the sixties had her first blood draw when she was in first grade. Unfortunately, science hadn't been improved up until the early nineties.. I think that if this would have been offered or, you know, come up with in the sixties, seventies, eighties, it could have been a complete game changer,' PCC RC Substance Abuse Counselor Kathy Hobbs said.
The Alzheimer's association estimates that nearly 11 percent of adults 65 and over in Bay County have Alzheimer's. Some warning signs for the disease include short-term memory loss that disrupts daily life, confusion with time or place, difficulty completing familiar tasks, and more.
'You don't just want a blood test, right? That's just one piece of information. You want to still have cognitive testing done. You want the doctor to be able to rule out certain things. That's not your hormones,' Wardlow said.
To learn more about Alzheimer's, you can visit here.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
9 minutes ago
- Yahoo
Intermountain Health launches cancer treatment program for patients with advanced melanoma skin cancer
SALT LAKE CITY, Utah (ABC4 Utah) – May is Melanoma Awareness Month and Intermountain Health is unveiling an exciting new treatment program for Utahns with advanced melanoma cancer – the first time local patients have been treated with this advanced technology and new therapy in the Beehive State. Thanks to this new cutting-edge personalized cancer treatment program, Utahns who have advanced melanoma cancer no longer have to leave the state to get a groundbreaking new treatment that is showing promise for patients with the deadliest type of skin cancer. Intermountain Health has launched a new program to provide tumor-infiltrating lymphocyte (TIL) therapy to treat patients with a type of skin cancer called unresectable or metastatic melanoma that cannot be removed surgically or has spread to other parts of the body. It is the first time this therapy has been used to treat patients in Utah. This novel therapy works by using special immune cells, called lymphocytes, which are taken from the tumor itself. These cells are then multiplied in a lab and put back into the patient's body to help fight the cancer. As part of the treatment process, doctors use AMTAGVI, the first and only FDA-approved prescription medication for the treatment of advanced melanoma that has not responded to standard therapies. AMTAGVI activates the patient's own immune system to target and destroy cancer cells and represents a different approach compared to other immunotherapies. Instead of broadly stimulating the immune system, it harnesses a patient's own tumor-specific T cells to directly target and destroy cancer cells. Intermountain Health cancer experts say the groundbreaking treatment marks a significant advancement in the fight against advanced melanoma, offering a new option for patients with limited treatment alternatives. 'We're excited to offer this advanced therapy and the hope it provides for improved outcomes for patients who have not responded to standard therapies,' said Tawnya Bowles, MD, a surgical oncologist at Intermountain Health. 'The promise for patients is that this treatment will work against their advanced melanoma when other treatments have failed. These patients do not have as many treatment options once their tumor has progressed on standard treatments. This therapy offers new hope for these patients.' TIL therapy has been used for decades, but AMTAGVI allows the treatment to extend beyond select treatment centers by using a protocol that lets a patient's tumor T cells grow at centralized facilities in the United States. Previously, only limited academic facilities with lab facilities could grow and expand the T cells. For Utahns, having the therapy program available locally is a major advancement. Not only does Utah have the highest incidence of melanoma in the nation, but until now, Utahns needing TIL therapy had to travel out of state for their care. 'Each year we see Utah patients who need this next step of treatment for advanced melanoma, and these patients previously had to leave the state and incur the expense of travel and the increased stress of being away from home,' said Caroline Nebhan, MD, PhD, Intermountain Health medical oncologist. 'We're thrilled to be able to offer this advanced treatment close to home with our Intermountain Health oncology team.' Patients in the new Intermountain treatment program are supported by a multi-disciplinary team of clinicians, including oncology experts and patient navigators, who work closely with patients throughout their treatment. The therapy involves surgically removing a sample of the patient's tumor, from which tumor-infiltrating lymphocytes (TILs) are extracted. These TILs, which are immune cells capable of recognizing and attacking cancer cells, are then sent to a specialized manufacturing facility where they are expanded and multiplied into billions of cells. Once the manufacturing process is complete (approximately 34 days), the patient undergoes a short course of lymphodepleting chemotherapy to prepare their body for the infusion of the expanded TILs. Following the AMTAGVI infusion, patients may receive several doses of interleukin-2 (IL-2) to further stimulate the activity and growth of the infused T cells. Patients are cared for in the hospital for a period to monitor for potential side effects. Research results of the medication were promising. Clinical trial data supporting FDA approval of AMTAGVI demonstrated promising response rates and, in many cases, prolonged outcomes in patients with advanced melanoma, suggesting the potential for long-term control of the disease. 'We're committed to providing our patients with access to the most advanced and innovative cancer treatments,' said Dr. Bowles. 'The addition of AMTAGVI to our comprehensive oncology program underscores this commitment and offers new hope for patients battling advanced melanoma.' To learn more about cancer care at Intermountain Health, go to Close Thanks for signing up! Watch for us in your inbox. Subscribe Now Sponsored by Intermountain Health. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
19 minutes ago
- Yahoo
Blood test for Alzheimer's could soon be available on the NHS
A new blood test for Alzheimer's disease has been found to accurately detect early symptoms of the illness, according to new research. Experts from the Mayo Clinic in the US examined two proteins in blood plasma – amyloid beta 42/40 and p-tau217 – which are associated with amyloid plaque build-up, a hallmark of Alzheimer's disease, to provide further evidence that blood tests can accurately diagnose dementia. The study, which was carried out on more than 500 people in an outpatient memory clinic, found the blood test was highly accurate, with 95 per cent sensitivity. That means it was 95 per cent accurate in picking up people with memory problems, with very few cases missed. It was also 82 per cent for specificity, meaning it was also highly accurate in ruling out people without dementia. The blood test has already been approved by the Food and Drug Administration regulator in the US. Dr Gregg Day, who led the study in the Alzheimer's and Dementia journal, said the test was as good as more invasive tests currently in use. 'When performed in the outpatient clinical setting, this is similar to the accuracy of cerebrospinal fluid biomarkers of the disease and is much more convenient and cost-effective.' Overall, researchers found that p-tau217 levels were higher in patients with Alzheimer's disease versus those without the disease. Dr Day said the next steps in the research were to evaluate blood-based testing in more diverse patient populations and people with early Alzheimer's who show no cognitive symptoms. Dr Richard Oakley, associate director for research and innovation at the Alzheimer's Society in the UK, said the results 'suggest this test is very accurate' and could be used alongside other tests and observations from a trained health professional. 'While focused on Alzheimer's disease, the test was evaluated in people with other types of dementias too, showing that it may help with differentiate causes of cognitive decline – though more research in diverse groups of individuals and in community-based setting is still needed. 'Currently diagnosis options in the UK are often slow, expensive and can be invasive, meaning thousands miss out on the benefits one can bring. 'It's great to see blood tests like this approved for clinical use in the US – we hope to see the same in the NHS, which is why we're part of the Blood Biomarker Challenge.' The Blood Biomarker Challenge is a multi-million-pound research programme supported by the Alzheimer's Society, Alzheimer's Research UK and the National Institute for Health and Care Research. Its goal is to bring blood tests for dementia diagnosis to the NHS by 2029. Dr Julia Dudley, head of research at Alzheimer's Research UK, said: 'We urgently need to improve how we diagnose dementia and it's great to see international research working towards this goal. 'Blood tests in this study look at p-tau217 and amyloid beta 42/40, and showed the tests offered high accuracy in confirming Alzheimer's disease. 'This study adds to the growing evidence that blood tests can detect the diseases that cause dementia in people with early memory and thinking problems. 'An important point to consider is that people taking part in research don't always reflect the full diversity of those affected by dementia, who might have additional conditions or other characteristics. 'That is why work is needed to understand whether these blood tests work in a real-world setting.'
Yahoo
an hour ago
- Yahoo
HistoSonics completes pivotal histotripsy system trial enrolment
As reports of an acquisition by one of the leading players in the medical device space percolate, HistoSonics has completed enrolment in a pivotal trial to evaluate its histotripsy platform in treating kidney tumours. The US company's prospective, multi-centre, single-arm pivotal #HOPE4KIDNEY (NCT05820087) trial is designed to evaluate the effectiveness and safety of the Edison system for the destruction of kidney tissue by treating primary solid renal tumours. A total of 67 patients have been enrolled with a single, non-metastatic solid kidney mass ≤3cm. Patients will be treated with the Edison system and followed for five years post-procedure, with data at the 90-day evaluation point to be submitted in support of regulatory approval with the US Food and Drug Administration (FDA). The Edison system uses a technology called histotripsy, involving the delivery of non-thermal, non-invasive focused ultrasound waves to target and eliminate cancerous liver tissue. The system received de novo clearance from the US Food and Drug Administration (FDA) in 2023 and last month secured its first major insurance coverage from a new healthcare policy from Healthcare payor Blue Cross Blue Shield of Michigan (BCBSM) and health plan option Blue Care Network. HistoSonics' vision is for its Edison system to become a 'foundational, non-invasive' solution across a range of clinical applications, the company's CEO, Mike Blue stated. 'Completing enrolment in our pivotal kidney tumour trial represents a significant milestone toward that goal and reinforces our confidence in expanding histotripsy into additional tumour types and indications,' said Blue. In May, Edison histotripsy system has been granted controlled early limited market access in the UK under an Unmet Clinical Need Authorisation (UCNA) under the UK's Innovative Devices Access Pathway (IDAP), launched by the UK Government in 2023 to help fast-track 'transformative medical technologies' into the healthcare system. As first reported by the Financial Times last month, HistoSonics is seeking a valuation of more than $2.5bn for a takeover of the company, with Medtronic, GE HealthCare and Johnson & Johnson (J&J), a longtime backer of HistoSonics, among the interested parties evaluating the business. J&J most recently participated in HistoSonics' $102m Series D funding round. "HistoSonics completes pivotal histotripsy system trial enrolment" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
